Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

Published:2023-06-17 Issue:4 Volume:18 Page:505-515
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Chiu Chao-Hua,Lin Meng-Chih,Wei Yu-Feng,Chang Gee-Chen,Su Wu-Chou,Hsia Te-Chun,Su Jian,Wang Anne Kuei-Fang,Jen Min-Hua,Puri Tarun,Shih Jin-Yuan

Funder

This study was funded by Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00975-5.pdf

Reference38 articles.

1. World Health Organization. Cancer. 2022. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 11 May 2022.

2. Taiwan Ministry of Health and Welfare. Cause of death statistics. 2019. https://www.mohw.gov.tw/cp-4650-50697-2.html. Accessed 11 May 2022.

3. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–72. https://doi.org/10.1016/S1470-2045(14)71180-5.

4. Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Canc Res. 2015;4(2):110. https://doi.org/10.3978/j.issn.2218-6751.2015.01.01.

5. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46. https://doi.org/10.1093/jnci/dji055.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

2. Application of combined erlotinib and bronchoscopic interventional therapy in the treatment of bronchial lung cancer;Tropical Journal of Pharmaceutical Research;2024-04-14